A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER

Brief description of study

The purpose of the study is to determine and investigate the safety, tolerability and efficacy of REGN5093-M114, a METxMET ADC, in patients with MET-overexpressing advanced NSCLC. This study may be amended at a later date to include patients with other tumor types that overexpress MET. We want to know a maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) of REGN5093-M114 in patients with mesenchymal epithelial transition factor (MET) overexpressing non-small cell lung cancer (NSCLC). We also want to assess preliminary anti-tumor activity of REGN5093-M114 in MET-overexpressing NSCLC as measured by the objective response rate. The study drug REGN5093-M114 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.